Trialynx Wins Forge’s DPHARM Idol Disrupt 2026

BOSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) -- This morning, Trialynx was announced as the winner of DPHARM Idol Disrupt at the 16th annual DPHARM: Disruptive Innovations to Modernize Clinical Research 2026 event. DPHARM is a part of Forge’s Fierce Life Sciences.

“DPHARM Idol Disrupt is disruptive innovation in action, not just words. It's a wonderful platform that showcases our brightest ideas and hopes as an industry. It brings together sponsors, sites, patients and solution providers and pushes all to do better together,” said judging moderator Sean Lynch, Innovative Capabilities Head, Innovative Trial Operations, Novartis.

Trialynx represented by Angie Schwab, MS, PMP, Founder and CEO, demonstrated how its technology is accelerating study startup and reducing the manual effort required to design and document clinical trials.

"We are incredibly honored to receive the DPHARM Idol Award. Being part of DPHARM Idol challenged us not only in how we build technology and bring it to the world, but in how we make it accessible. Our mission is to bring sponsors, CROs, and sites together in one shared digital experience that everyone can be part of. Once you experience what’s possible when we move beyond documents and work from shared, real-time information, there’s no denying the power of a digital future,” said Angie Schwab, MS, PMP, Founder and CEO, Trialynx.

The competition was fierce as the six DPHARM Idol Disrupt finalists each had six minutes to present how they are solving critical challenges in clinical development before a panel of judges representing pharmaceutical sponsors, healthcare organizations, patient advocates, and life science investors.

"Trialynx is more than a digital protocol solution; it is a collaboration platform that unites the early upstream study design work of clinical development with the downstream study startup and operational planning of clinical operations. Furthermore, Trialynx helps companies realize the benefits of Digital Data Flow with CDISC USDM support from an ICH M11 with the downstream study startup and operational planning of clinical operations. Furthermore, Trialynx helps companies realize the benefits of Digital Data Flow with CDISC USDM support from an ICH M11-compliant structured protocol design," said Joe Dustin, Senior Director, Digital Clinical Development, Sanofi, and a 2026 DPHARM Idol Disrupt judge.

“Trialynx can transform clinical trials by turning fragmented, document-based study design into an intelligent, structured digital workflow that enables faster, better-informed and more efficient trials,” said Ventislav Dobrev, Global Clinical Integration Lead, Digital Biomarkers, Roche.

The DPHARM Idol Disrupt 2026 finalists:

• Areti Health, represented by Ilya Gluhovsky, PhD, Co-Founder and CEO
• Deep Intelligent Pharma, represented by Brooklyn Montgomery, Director, Business Development
• Delve Health, represented by Nico O'Kuinghttons, Chief Commercial Officer
• Loopa Logic, represented by Steven Moreno, Co-founder
• Tilda Research, represented by Ram Yalamanchili, CEO and Founder
• Trialynx, represented by Angie Schwab, MS, PMP, Founder and CEO

The DPHARM Idol Disrupt 2026 judges:

• Tiffany Bratts, EdD, MPH, MS, Director, Clinical Patient Engagement and Inclusion, Gilead
• Elspeth Carnan, PhD, VP, Trial Delivery Support, Bristol Myers Squibb
• Martina DiMeglio, Clinical Research Lead, Clinical Trials Office, Sidney Kimmel Comprehensive Cancer Center at Jefferson Health
• Ventsislav Dobrev, Global Clinical Integration Lead, Digital Biomarkers, Roche
• Joe Dustin, Senior Director, Digital Clinical Development, Sanofi
• Esther Dyson, Author, In Defense of Limits: Human Time and AI Scale (2027)
• Yusuf Ghadiali, Executive Director, Global Clinical Operations & Planning, Daiichi Sankyo
• Hassan Kadhim, Executive Director, Clinical Operations Process and Performance Excellence, Summit Therapeutics
• Sabina Kineen, Patient Advocate, Lived-experience Expert, Fabry Support & Information Group
• Doug Schantz, Head of Clinical Key Relationship Excellence, Bayer
• Anthony K. Taylor, DHSc, MSPharm, PMP, Director, Clinical Site and Patient Insights, AbbVie
• Donna Usiskin, Chief Strategy Officer, New Enterprise Ventures

The moderator of judges was Sean Lynch, Innovative Capabilities Head, Innovative Trial Operations, Novartis.

For more information on DPHARM, visit DPHARMConference.com.

About DPHARM
DPHARM^®: Disruptive Innovations to Modernize Clinical Research offers an unparalleled opportunity to hear senior clinical operations executives and innovative thought leaders report on innovations that are modernizing clinical trials and reducing patient burden. The concept of DPHARM was founded by Pfizer and Johnson & Johnson, who continue to play a key role on the steering committee to deliver a highly relevant and engaging program. DPHARM takes place September 15-16 at the Sheraton Boston Hotel in Boston, MA.

About Forge
Forge is a leading global B2B events and media company, connecting buyers and sellers across high-value industries through live events, trusted media brands, digital products and year-round communities. Powered by first-party data, technology and deep market expertise, Forge helps businesses discover opportunities, build the right relationships and stay engaged well beyond the event itself. It is a company guided by a single purpose, Moving Markets.

For more information, visit forgelive.com.

Media Contact
Allyson Adams
DPHARM
aadams@questex.com